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Background: Hepatitis C virus (HCV) is a public health problem with almost 185 million people estimated to be
infected worldwide and is one of the leading causes of hepatocellular carcinoma. Currently, there is no vaccine for
HCV infection and the current treatment does not clear the infection in all patients. Because of the high diversity of
HCV, protective vaccines will have to overcome significant viral antigenic diversities. The objective of this study was
to predict T-cell epitopes from HCV genotype 5a sequences.
Methods: HCV near full-length protein sequences were analyzed to predict T-cell epitopes that bind human
leukocyte antigen (HLA) class I and HLA class II in HCV genotype 5a using Propred I and Propred, respectively. The
Antigenicity score of all the predicted epitopes were analysed using VaxiJen v2.0. All antigenic predicted epitopes
were analysed for conservation using the IEDB database in comparison with 406, 221, 98, 33, 45, 45 randomly
selected sequences from each of the HCV genotypes 1a, 1b, 2, 3, 4 and 6 respectively, downloaded from the
GenBank. For epitope prediction binding to common HLA alleles found in South Africa, the IEDB epitope analysis
tool was used.
Results: A total of 24 and 77 antigenic epitopes that bind HLA class I and HLA class II respectively were predicted.
The highest number of HLA class I binding epitopes were predicted within the NS3 (63%), followed by NS5B (21%).
For the HLA class II, the highest number of epitopes were predicted in the NS3 (30%) followed by the NS4B (23%)
proteins. For conservation analysis, 8 and 31 predicted epitopes were conserved in different genotypes for HLA
class I and HLA class II alleles respectively. Several epitopes bind with high affinity for both HLA class I alleles and
HLA class II common in South Africa.
Conclusion: The predicted conserved T-cell epitopes analysed in this study will contribute towards the future
design of HCV vaccine candidates which will avoid variation in genotypes, which in turn will be capable of inducing
broad HCV specific immune responses.
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Hepatitis C virus (HCV) is estimated to infect 185 million
people worldwide [1]. Chronic HCV infection leads to
progressive liver disease, being one of the major causes of
hepatocellular carcinoma and one of the most common
indications for liver transplantation [2]. The World Health
Organization (WHO) strongly recommends combination
therapy with pegylated interferon and ribavirin for
chronically infected patients who qualify for treatment* Correspondence: selokela.selabe@ul.ac.za
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unless otherwise stated.[1]. Recently, two NS3 protease inhibitors (boceprevir
and telaprevir) have been approved by the US Food
and Drug Administration, and the WHO conditionally
(until more evidence has accumulated) recommends
that these drugs should be given in combination with
pegylated interferon and ribavirin for the treatment of
chronic HCV genotype 1 infections. Also, the WHO
strongly recommends that sofosbuvir be given in com-
bination with ribavirin alone in patients who cannot
tolerate interferon and are chronically infected with
genotypes 1, 2, 3 and 4 [1]. However, these therapies
are still not affordable in most developing countries.tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Gededzha et al. Virology Journal 2014, 11:187 Page 2 of 13
http://www.virologyj.com/content/11/1/187As a result, the development of an effective HCV vac-
cine is undoubtedly the best solution for the ultimate
control of HCV infections, and is a public health
priority.
Prophylactic vaccines against viral infections are
generally aimed at inducing a humoral (B-cell) immune
response, while therapeutic vaccines preferably activate
both humoral and cellular (T-cell) immune responses
[3]. A successful HCV vaccine will need to stimulate
both arms of the adaptive immune response, since while
both cellular and humoral .immune responses occur in
a naturally infected host, the current consensus is that a
strong cellular response is vital for viral clearance and
protection [4].
The development of an effective HCV vaccine requires
an understanding of the host’s adaptive immune response
to natural infection. As with other viral infections, viral
antigens are presented to CD4+ and CD8+ T-cells via
human leukocyte antigen (HLA) class II and class I
molecules, respectively [5]. Different HLA class alleles
have been found to be associated with HCV infection.
For example, HLA-A*11, HLA-Cw*04 and HLA-B*53
have been associated with HCV persistence [6,7], while
HLA-B*27, HLA-A*11:01, HLA-B*57, HLA-Cw*01:02
and HLA-A*03 have been associated with spontaneous
HCV clearance [8,9]. Also, HLA-DRB1*11 and HLA-
DQB1*03:01 have been associated with decreased dis-
ease severity of HCV infection globally, suggesting they
may present HCV-derived epitopes more efficiently to
CD4+ T-cells than others and thus capable of viral
clearance [10]. During acute HCV infection, develop-
ment and persistence of strong specific responses by
CD8+ and CD4+ T-cells [11,12] and neutralizing anti-
bodies [13] are associated with viral clearance, with
HCV-specific CD8+ and CD4+ T-cells usually being
transient or absent in patients who develop persistent
infections. The rate of chronic liver disease progression
has been shown to be determined by the magnitude of
HCV-specific CD4+ T-cell responses, since these cells
are essential for both the cellular and humoral responses
[14]. CD8+ T-cells are essential for long-term protection
against chronic HCV [15], while CD4+ T-cells play a role
in viral clearance [16].
HCV infection evades the host’s immune system by
generating immune escape variants through alteration
of the virus HLA-restricted epitopes to avoid being
recognized by T-cells and neutralizing antibodies [14].
Thus effective HCV vaccines will need to target pro-
tective epitopes that display minimal cross-genotype
amino acid variability as they will provide broad po-
tency [17]. Peptides corresponding to protective epi-
topes are desirable vaccine candidates because they are
easy to construct and produce, and they do not contain
infectious materials [18]. The first step in the processof epitope-based vaccine design and development is
the in-silico prediction of peptide binding affinities to
HLA proteins [19].
Genotype 5 accounts for over 50% of HCV infections
in South Africa [20], and is becoming more prevalent in
Europe and North America [21]. It is the most con-
served of HCV genotypes, being classified into only one
subtype (5a) [22-24]. The growing prevalence of HCV
genotype 5a in different parts of the world necessitates
its molecular characterization in order to improve the
formulations of vaccine candidates that are in develop-
ment. Thus the aim of this study was to assess immuno-
logical determinants by predicting conserved epitopes
in near-full length HCV genotype 5a sequences using a
suite of online programmes to help in the designing of
new vaccine candidates.
Results
Prediction of T-cell epitopes
For HLA class I, a total of 24 antigenic epitopes were
predicted in the consensus near full-length of genotype
5a (Table 1). Epitope NS31325–1333 covered 30 of the 47
HLA class I alleles that were analysed assuring high
binding affinity to different alleles. For conservation
analysis with other genotypes, 8 of 24 epitopes were
100% conserved for specific genotypes. Epitopes
NS31332–1340 and NS5B2557–2565 were highly conserved
in all genotypes analysed, and epitope E2684–692 was
conserved in all genotypes except for genotype 2, while
5 other epitopes were conserved in either 2 or 3 geno-
types analysed. In addition epitope NS4B1832–1840 was
conserved in genotype 1a, 1b, 2 and 4 epitope variants
at anchor residues position 2 and 9 while E2677–685,
NS31325–1333 and NS31357–1365 were conserved in at
least 3 genotypes epitope variants each (Table 1). For
HLA class II, 77 epitopes were predicted (Table 2). Epi-
tope NS4B1879–1887 and NS4B1880–1888 covered 51 of 51
HLA class II alleles analysed. For conservation analysis
with other genotypes, 31 of 71 epitopes were conserved
for specific genotypes. Some epitopes were highly con-
served in all genotypes (E2507–515, E2509–517, NS31253–1261,
NS31254–1262, NS31327–1335, NS31392–1400, NS4B1916–1924
and NS4B1919–1927), while other epitopes were con-
served in at least 1 to 4 of the genotypes analysed. Epi-
tope NS4B1886–1894 was conserved at anchor residues
position 1, 4, 6 and 9 in all 6 genotypes epitope vari-
ants while E2692–700, NS2964–972, NS31418–1426 and
NS41561–1569 were conserved in at least 5 genotypes
epitope variants each (Table 2). Epitopes NS31585–1593,
NS5A2285–2293 and NS5B2889–2897 were predicted to
cover both HLA class I and HLA class II alleles. The
highest number of HLA class I binding epitopes were
predicted within the NS3 (63%), followed by NS5B
(21%), and for the HLA class II, the highest number of
Table 1 HLA class I predicted epitopes of HCV genotype 5a and their antigenicity prediction score, number of allele and conservation (in percentages) in
different genotypes
Position Epitope sequence No of allele Antigenecity score Genotype 1a Genotype 1b Genotype 2 Genotype 3 Genotype 4 Genotype 6
E2
651 RCDLEDRDR 9 2.7428
677 CSFTPTPAL 27 0.8772 CSFTTLPAL (94) CSFTTLPAL (92) CSFTPMPAL (73)
684 ALSTGLIHL# [25-27] 29 0.9005 ALSTGLIHL (70) ALSTGLIHL (99) ALSTGLIHL (97) ALSTGLIHL (97) ALSTGLIHL (84) ALSTGLIHL (91)
NS2
861 VPPLQVRGG 6 1.4312 VPPLNVRGG (85)
NS3
1032 YAQQTRGVL 26 0.7638 YAQQTRGLL (99)
1033 AQQTRGVLG 5 0.7751 AQQTRGLLG (99)
1128 ADLYLVTRH 5 1.0277 SDLYLVTRH (99) SDLYLVTRH (99) VDLYLVTRN (92)
1325 TILGIGTVL 30 0.7555 SILGIGTVL (93) TILGIGTVL (88) SILGIGTVL (94) TILGIGTVL (82)
1332 VLDQAETAG 5 0.5004 VLDQAETAG (96) VLDQAETAG (98) VLDQAETAG (96) VLDQAETAG (100) VLDQAETAG (93) VLDQAETAG (71)
1357 TPHPNIEEV 24 0.8423 VPHPNIEEV (89) VPHPNIEEV (80) VPHSNIEEV (94)
1359 HPNIEEVAL# [28-31] 24 1.1654 HPNIEEVAL (88) HPNIEEVAL (76) HSNIEEVAL (94)
1370 EGEIPFYGR 9 1.0560 TGEIPFYGK (97)
1374 PFYGRAIPL 7 0.9479 PFYGKAIPL (99) PFYGKAIPI (85) PFYGKAIPL (82) PFYGKAIPL (73)
1642 TKYIMACMS 6 0.7008 PFYGKAIPL (99) TKYIMACMS (70) TKYIMACMS (70) TKYIMACMS (93) TKYIMTCMS (87)
NS4B
1712 SASLPYMDE 5 0.5488
1819 QIAPPTAAT 5 0.5293 QLAAPGAAT (99) QLAPPSAAS (94) QIAPPAGAT (91) QIATPTAST (89)
1832 SGMAGAAVG 5 0.8750 AGLAGAAIG (81) AGIAGAAVG (93) SGLVGAAVG (98) SGLAGAAIG (76)
1848 LIDILAGYG 5 0.8431 LVDILAGYG (94) LVDILAGYG (95) LLDILAGYG (79) LVDILAGYG (84)
1854 GYGAGVAGA 9 0.5562 GYGAGVAGA (99) GYGAGVAGA (99) GYGAGVSGA (94) GYGAGVAGA (91) GYGAGVSGA (84)
NS5B
2522 GYGAKEVRS 7 1.3540 GYGAKDVRC (95) GYGAKDVRN (84) GFGAKEVRS (93) GYSAKDVRS (79)
2557 TIMAKNEVF# [32] 12 0.6303 TIMAKNEVF (99) TIMAKNEVF (80) TIMAKNEVF (83) TIMAKNEVF (100) TIMAKNEVF (84) TIMAKNEVF (93)
2568 EPSKGGKKP 6 1.4218 QPEKGGRKP (93)
2720 LASCRAAKL 28 0.5264
2886 LHGLSAFSL 11 0.6732 LHGLSAFSL (99) LHGLSAFSL (98) LHGLSAFTL(82) LHGMAAFSL (98)
#-indicates that the epitope has been experimentally proven to be a true positive.
Bold- indicates percentage of epitope that is 100% conserved in more than 70% of the sequences analysed in each genotype.















Table 2 HLA class II predicted epitopes of HCV genotype 5a and their antigenicity prediction score, number of allele and conservation (in percentages) in
different genotypes




Genotype 1a Genotype 1b Genotype 2 Genotype 3 Genotype 4 Genotype 6
E1
320 WDMMMNWSP 10 1.3610 WDMMMNWSP (99) WDMMMNWSP (97) WDMMMNWSP (97) WDMMMNWSP (93) WDMMMNWSP (93)
E2
507 YCFTPSPVV 6 1.2112 YCFTPSPVV (93) YCFTPSPVV (98) YCFTPSPVV (88) YCFTPSPVV (100) YCFTPSPVV (91) YCFTPSPVV (91)
509 FTPSPVVVG 17 1.3553 FTPSPVVVG (94) FTPSPVVVG (98) FTPSPVVVG (88) FTPSPVVVG (100) FTPSPVVVG (89) FTPSPVVVG (73)
665 LLHTTTQWA 5 0.6616 LLLSTTQWQ (100) LLHSTTELA (73) LLLSTTQWQ (73)
666 LHTTTQWAI 25 0.5863 LLTTTQWQI (100) LHSTTELAI (73)
692 LHQNIVDTQ 6 0.8564 LHQNIVDVQ (100) LHQNIVDVQ (73) LHQNIVDVQ (95) LHQNIVDVQ (100) LHQNIVDVQ (87)
739 LLVCQAEAA 22 0.5506 LLISQAEAA (100) LLIAQAEAA (72) LMISQAEAA (73)
P7
803 LPHRALALD 7 0.6966 LPQRAYALD (100) LPPRAYAMD (86)
NS2
860 WVPPLQVRG 7 1.1998 WVPPLNVRG (100) WVPPLLARG (82)
861 VPPLQVRGG 25 1.4312 VPPLNVRGG (100)
864 LQVRGGRDA 20 0.6368 LNVRGGRDA (100) LNVRGGRDA (86)
880 FHPALGFEI 19 1.4374 VHPALVFDI (99)
892 LLGILGPLY 14 0.5940 LLAVLGPLW (100) LIAVLGPLY (82)
895 ILGPLYLLQ 5 0.8264 VLGPLWVLQ (99) VLGPLYLIQ (88)
938 LLHLGRLTG 25 0.5554
964 LRDLAVATE 9 1.0497 LRDLAVAVE (100) LRDLAVAVE (93) LRDLAVAVE (85) LKDLAVATE (73) LRDLAVAVE (93)
997 LAGLPVSAR 11 0.9120 INGLPVSAR (100) LCGLPVSAR (100)
1025 LLAPITAYA 22 0.5253 LLAPITAYA (99) LLAPITAYA (79) LLAPITAYA (89)
NS3
1047 LTGRDKNEA 22 1.5633 LTGRDKNQV (100) LTGRDKNQV (93) LTGRDKNVV (90)
1131 YLVTRHADV# [33-35] 15 0.7569 YLVTRHADV (99) YLVTRHADV (99) YLVTRNADV (97)
1152 LLSPRPISY 5 2.2999 LLSPRPISY (99) LLSPRPVSY (73) LLSPRPLST (89)
1153 LSPRPISYL 5 1.3109 LSPRPISYL (99) LSPRPVSYL (73) LSPRPLSTL (89)
1253 VLNPSVAAT 14 1.2489 VLNPSVAAT (100) VLNPSVAAT (100) VLNPSVAAT (97) VLNPSVAAT (100) VLNPSVAAT (96) VLNPSVAAT (89)
1254 LNPSVAATL 6 0.9169 LNPSVAATL (100) LNPSVAATL (100) LNPSVAATL (98) LNPSVAATL (100) LNPSVAATL (95) LNPSVAATL (89)
1258 VAATLGFGA 11 1.2617 VAATLGFGA (90) VAATLGFGA (85) VAATLGFGA(98)















Table 2 HLA class II predicted epitopes of HCV genotype 5a and their antigenicity prediction score, number of allele d conservation (in percentages) in
different genotypes (Continued)
1264 FGAYMSKAY 14 0.6561 FGAYMSKAH (100) FGAYMSKAH (82)
1327 LGIGTVLDQ 42 0.5607 LGIGTVLDQ (97) LGIGTVLDQ (88) LGIGTVLDQ (98) LGIGTVLDQ ( ) LGIGTVLDQ (93) LGIGTVLDQ (96)
1373 IPFYGRAIP 16 0.5679 IPFYGKAIP (100) IPFYGKAIP (93) IPFYGKAIP (81)
1375 FYGRAIPLA 22 1.0280 FYGKAIPLE (100) FYGKAIPIE (81) FYGKAIPLE (71)
1392 IFCHSKKKC 22 1.5437 IFCHSKKKC (93) IFCHSKKKC (94) IFCHSKKKC (95) IFCHSKKKC IFCHSKKKC (80) IFCHSKKKC (93)
1415 VAYYRGLDV 21 0.8250 VAYYRGLDV (98) VAYYRGLDV (96) VAYYRGLDV (92) VAYYRGLDV ) VAYYRGLDV (91) VAFYRGVDV (89)
1418 YRGLDVAVI 51 1.0522 YRGLDVSVI (100) YRGLDVSVI (97) YRGLDVSVI (84) YRGLDVSVI ( YRGLDVSVI (91) YRGVDVSVI (67)
1482 VSRSQRRGR 12 2.0649 VSRTQRRGR (100) VSRSQRRGR (93) VSRSQRRGR (96) VSRSQRRGR ) VSRSQRRGR (98) VSRSQRRGR (73)
1561 VFTGLTNID 9 1.1689 VFTGLTHID (100) VFTGLTHID (96) VFTGLTHID (98) VFTGLTHID VFTGLTHID (89)
1583 FPYLVAYQA 24 0.6584 FPYLVAYQA (85) FAYLVAYQA (78)
1585 YLVAYQATV# [25,39] 17 0.5020 YLVAYQATV (99) YLVAYQATV (85) YLTAYQATV (70) YLVAYQATV (87) YLVAYQATV (91)
1586 LVAYQATVC 28 0.6052 LVAYQATVC (99) LVAYQATVC (85) LVAYQATVC (82) LVAYQATVC (91)
1631 VQNEITLTH 35 1.1979 VQNEVTLTH (100) VQNEVTLTH (80)
1641 ITKYIMACM 8 0.6964 VTKYIMTCM (100) VTKYIATCM (94) ITKYIMACM (75) ITKYIMTCM (87)
1645 IMACMSADL 22 0.8406 IMTCMSADL (100) IMACMSADL (82) IATCMQADL (99) IMACMSADL ) IMACMSADL (93) IMTCMSADL (87)
NS4B
1733 LGLIGTAGQ 43 1.2450
1765 MWNFVSGIQ 18 1.2300 MWNFISGIQ (100) MWNFISGIQ (95) MWNFISGIQ (96) MWNFVSGIQ ) MWNFISGIQ (87)
1766 WNFVSGIQY 22 0.6246 WNFISGIQY (100) WNFISGIQY (95) WNFISGIQY (96) WNFVSGIQY ) WNFISGIQY (87) WNFVSGIQY (91)
1791 MSFTAAVTS 8 0.7414 MAFTAAVTS (100) MAFTASITS (88) MAFSAALTS (93) MAFTASVTS MSFTAAVTS (93)
1812 LGGWVASQI 16 0.608 LGGWVAAQL (100) LGGWVAAQL (95) LGGWVATHL LGGWVASQI (96)
1849 IDILAGYGA 9 0.7525 VDILAGYGA (100) VDILAGYGA (97) LDILAGYGA VDILAGYGA (84)
1863 LVAFKIMCG 47 1.0160 LVAFKIMSG (100) LVAFKIMSG (95) LVAFKIMGG ( VVTFKIMSG (89) LVAFKIMSG (84)
1879 LVNLLPSIL 51 0.7592 LVNLLPAIL (100) LVNLLPAIL (90) MVNLLPAIL LVNLLPAIL (73)
1880 VNLLPSILC 51 0.9874 VNLLPAILS (100) VNLLPAILS (92) VNLLPAILS ( VNLLPAILS (89) VNLLPALLS (82)
1883 LPSILCPGA 6 0.7104 LPAILSPGA (100) LPAILSPGA (99) LPAILSPGA (74) LPAILSPGA (1 LPAILSPGA (89) LPALLSPGA (84)
1886 ILCPGALVV 9 0.9365 ILSPGALVV (100) ILSPGALVV (99) ILSPGALVV (98) ILSPGALVV (1 ILSPGALVV (91) LLSPGALVV (89)
1892 LVVGVICAA 30 0.7097 LVVGVVCAA (100) LVVGVVCAA (98) LVVGVICAA (97) LVVGVICAA LVVGVVCAA (89) LVVGVVCAA (93)
1893 VVGVICAAV 50 0.9530 VVGVVCAAI (100) VVGVVCAAI (96) VVGVICAAI (98) VVGVICAAI ( VVGVVCAAI (91) VVGVVCAAI (76)
1896 VICAAVLRR 35 0.9887 VVCAAILRR (100) VVCAAILRR (95) VICAAILRR (97) VICAAILRR ( VVCAAILRR (91) VVCAAILRR (76)
1897 ICAAVLRRH 12 1.2316 VCAAILRRH (100) VCAAILRRH (97) ICAAILRRH (97) ICAAILRRH ( VCAAILRRH (89)





































Table 2 HLA class II predicted epitopes of HCV genotype 5a and their antigenicity prediction score, number of allele and conservation (in percentages) in
different genotypes (Continued)
1919 LIAFASRGN 24 2.0235 LIAFASRGN (100) LIAFASRGN (99) LIAFASRGN (98) LIAFASRGN (100) LIAFASRGN (93) LIAFASRGN (96)
1922 FASRGNHVS 18 1.2938 FASRGNHVS (100) FASRGNHVS (98) FASRGNHVA (97) FASRGNHVS (94) FASRGNHVS (82) FASRGNHVS (93)
NS5A
1994 WLQAKLLPQ 33 1.1603 WLKAKLMPQ (100) WLQSKLLPR (84)
2101 YITGVTQDN 6 1.1358 YVTGMTTDN (100)
2105 VTQDNLKCP 6 1.0178 MTTDNLKCP (100)
2237 MGGNITRVE 20 1.2656 MGGNITRVE (92) MGGNITRVE (96) MGSNITRVE (91)
2285 LPVWARPGY 9 0.6143 LPIWARPDY (100) LPIWARPDY (78)
NS5B
2422 MSYSWTGAL 9 0.5749 MSYSWTGAL (76) MSYTWTGAL (94) MSYSWTGAL (97) MSYSWTGAL (85) MSYSWTGAL (91)
2451 LRHHNLVYS 40 1.2321 LRHHNLVYS (89) LRHHNMVYA (86) LRHHNLVYS (97)
2523 YGAKEVRSL 24 1.1739 YGAKDVRCH (100) YGAKDVRNL (85) FGAKEVRSL (92) YSAKDVRSL (76)
2559 MAKNEVFAV 18 0.8466 MAKNEVFCV (100) MAKNEVFCV (81) MAKNEVFCV (65) MAKNEVFCV (85) MAKNEVFCV (96)
2564 VFAVEPSKG 10 0.7925 VFCVQPEKG (100) VFCVQPEKG (89)
2637 FSYDTRCFD 11 15808 FSYDTRCFD (99) FSYDTRCFD (95) FSYDTRCFD (100) FSYDTRCFD (93) FSYDTRCFD (87)
2660 YQSCDLQPE 11 1.3802 YQCCDLDPQ (100) YQCCDLAPE (94)
2696 YRRCRASGV 41 1.2642 YRRCRASGV (99) YRRCRASGV (99) YRRCRASGV (98) YRRCRASGV (97)
2778 YDLELVTSC 6 1.0923 YDLELITSC (100) YDLELITSC (96) YDLELITSC (98) YDLELITSC (91) YDLELITSC (96)
2850 FSVLQSQEQ 21 0.8451 FSILLAQEQ (84) FSILQSQEA (78)
2871 VYSVTPLDL 29 2.0113 CYSIEPLDL (100) CYSIEPLDL (75) TYSVTPLDL (91) TYSITPLDL (87)
2883 IQRLHGLSA 50 0.4322 IQRLHGLSA (98) IQRLHGLSA (72) IQYLAGLST (93) IERLHGLSA (79) IQRLHGLSA (75) IQRLHGMAA (96)
2889 LSAFSLHSY# [40] 6 0.6007 LSAFSLHSY (99) LSAFSLHSY (97) LSAFTLHGY (80) MAAFSLHGY (89)
#-indicates that the epitope has been experimentally proven to be a true positive.
Bold- indicates percentage of epitope that is 100% conserved in more than 70% of the sequences analysed in each genotype.
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http://www.virologyj.com/content/11/1/187epitopes were predicted in the NS3 (30%) followed by
the NS4B (23%) proteins (Table 3).
Epitope binding affinity to common South African HLA
class I and HLA class II alleles
Genotype 5 epitopes and their genotypic variants were
analysed for their binding affinity to HLA class I and
HLA class II alleles most common in South Africa,
where genotype 5a is predominating. For HLA class I,
11 of the most common South African HLA-A alleles
(HLA-A*01:01, HLA-A*02:01, HLA-A*30:01 and HLA-
A*30:02), HLA-B (HLA-B*0702, HLA-B*08:01 and
HLA-B*3501), and HLA-C (HLA-C*04:01, HLA-C*06:01,
HLA-C*07:01 and HLA-C*07:02) were analysed. The limi-
tation of Propred 1 is that it does not cover most of the
main HLA class I alleles: HLA-A (HLA-A*01:01, HLA-
A*30:01 and HLA-A*30:02), HLA-B (HLA-B*08:01) and
HLA-C (HLA-C*04:01, HLA-C*06:01, HLA-C*07:01 and
HLA-C*07:02) that are observed in South Africa. As a
results the IEDB epitope analysis tool was used to predict
epitopes of all the 11 most common HLA-A, HLA-B,
HLA-C covering HLA class I alleles found in South Africa
with the ANN prediction server. Thirteen antigenic epi-
topes with high binding affinity score of <50 IC50nM were
predicted. Most epitopes bind with high affinity to single
HLA class I alleles with exception of epitope NS5B2889–2297
LSAFSLHSY that bind with high affinity to 2 HLA-A alleles
(HLA-A*01:01 and HLA-A*30:02). Four of the epitopes
binding to HLA-B*35:01 followed by HLA-A*02:01 with 3
epitopes binding to it, however, none of the epitopes bind
to HLA-C*04:01, HLA-C*06:01 and HLA-C*07:02 alleles.
The NS31359–1367 shows a level of promiscuity to HLA-A
and HLA-B alleles. NS31359–1367 HPNIEEVAL bind with
intermediate affinity to HLA-B*07:02, while its genotype 2,
3 and 4 variant HSNIEEVAL bind with poor affinity and
genotype 6 variant HPNITETAL bind with high affinity. For
HLA-B*35:01, the NS31359–1367 HPNIEEVAL and genotype
6 variant HPNITETAL bind with high affinity while
genotype 2, 3 and 4 variant HSNIEEVAL bind with poor
affinity. Three (E2684–692, NS31032–1040 and NS31359–1367)
of the thirteen epitopes were predicted by both Propred 1
and IEDB analysis tool (Table 4).
For HLA class II alleles, 4 most common HLA-DRB alleles
(HLA-DRB1*03:01, HLA-DRB1*04:01, HLA-DRB1*11:01
and HLA-DRB1*15:01) were analysed. Nineteen antigenicTable 3 Distribution of genotype 5a HLA class I and II predict
HLA class No of predicted epitopes Distribution
C E1 E2
I 24 0 (0) 0 (0) 3 (12)
II 77 0 (0) 1 (1) 6 (8)
aNumber of epitopes and their percentage in brackets.
bHCV gene with highest number of binding epitopes (in bold).epitopes with high binding affinity score of <50 IC50nM
were predicted. The HLA-DRB1*11:01 has the highest
number of binding epitopes (10) followed by HLA-
DRB1*04:01 and HLA-DRB1*15:01 (7 each). Epitopes
NS4B1919–1927 LIAFASRGN was predicted to be the most
promiscuous epitope binding to HLA-DRB1*04:01, HLA-
DRB1*11:01 and HLA-DRB1*15:01 with high affinity and
HLA-DRB1*03:01 with intermediate affinity. This epitope
is conserved in all genotypes. Epitopes E2507-515,
NS4B1774–1782, NS4B1919–1927, and NS4B1920–1928 were
highly conserved in all genotypes (Table 5).
Validation of epitopes
Seven of the predicted epitopes were previously confirmed
experimentally by other studies as true positives in com-
parison with the epitopes analysed in the IEDB resource
database. Majority of the epitopes predicted in this study
have not been previously tested experimentally. The ‘true
epitopes’ are highlighted by (#) in Tables 1, 2 and 4.
Discussion
Several studies that have published HCV epitopes focused
mainly on genotype 1 [41,42], but most of these studies do
not take into account the diversity in other genotypes that
are common in developing countries like most African
countries. In the present study, predicted antigenic epitopes
of HCV genotype 5a proteins from South Africa were
analysed followed by conservation with randomly se-
lected genotypes 1–6 references from GenBank. Several
studies have confirmed the importance of using immunoin-
formatics as good predictors for selecting HLA ligands, T-
cell epitopes and immunogenicity [43]. As a result, several
immunoinformatics methods have been developed to assist
in the identification of HLA binding peptides [44,45].
For this analysis, near full-length sequences covering
all HCV proteins with the exclusion of the 3′end of the
NS5B were included to maximize number of epitopes
predicted. The use of the whole viral genome for devel-
oping epitope vaccines has a potential control over the
immune response and eliminating the side effects [43],
and it also increases the chance of detecting a virus at
any developmental stage [46]. It has been shown that
multiple epitopes from different parts of the HCV genome
are important to produce a vaccine that can elicit strong
humoral immune responses and multiple specific cellulared epitopes in each of the HCV gene
of the predicted epitopes in each of the HCV genea
P7 NS2 NS3b NS4A NS4B NS5A NS5B
0 (0) 1 (4) 15 (63) 0 (0) 0 (0) 0 (0) 5 (21)
1 (1) 10 (13) 23 (30) 0 (0) 18 (23) 5 (7) 13 (7)
Table 4 Binding affinity scores of predicted epitopes and their variants to common HLA I allele types prevalent in South Africa

























684 ALSTGLIHL# [25-27] 1a, 1b, 3, 4,5a, 6 + +++ + + + + + + + + +
ALSTGLLHL 2 + +++ + + + + + + + + +
NS2
1025 LLAPITAYA 1a, 3, 4, 5a + +++ + ++ + + + + + + +
LLAPITAYT 2 + +++ + ++ + + + + + + +
NS3
1032 YAQQTRGVL 5a + + + + +++ + + + + + +
YAQQTRGLL 1a, 2 + + + + ++ + + + + + +
YSQQTRGLL 1b + + + + + + + + + + +
YAQQTRGLV 6 + + + + + + + + + + +
1242 AAYAAQGYK 1a, 1b, 4, 5a + + +++ + + + + + + + +
AAYASQGYK 2 + + +++ + + + + + + + +
1264 FGAYMSKAY 5a + + + + + + +++ + + + +
FGAYMSKAH 1a, 1b, 2 + + + + + + + + + + +
1359 HPNIEEVAL# [28-31] 1a, 1b, 5a + + + + ++ + +++ + + + +
HSNIEEVAL 2, 3, 4 + + + + + + + + + + +
HPNITETAL 6 + + + + +++ + +++ + + + +
1367 LPSEGEIPF 5a + + + + ++ +++ + + + +
LGHEGEIPF 2 + + + + + + ++ + + + +
LGSEGEIPF 3 + + + + + + ++ + + + +
LPTTGEIPF 4, 6 + + + + ++ +++ + + + +
1585 YLVAYQATV# [25,39] 1a, 1b, 4, 5a, 6 + +++ + + + + + + + + +
YLTAYQATV 2, 3 + +++ + + + + + + + + +
NS5A
1927 NHVSPTHYV 1a, 1b, 3, 4,5a, 6 + + + + + + + + ++ +++ +
NHVAPTHYV 2 + + + + + + + + + ++ +
2285 LPVWARPGY 5a + + + + + + +++ + + + +
LPIWARPDY 1a, 3, 4, 6 + + + + + + +++ + + + +















Table 4 Binding affinity scores of predicted epitopes and their variants to common HLA I allele types prevalent in South Africa (Continued)
NS5B
2696 YRRCRASGV 1a, 1b, 2, 3, 5a + + + + + ++ + + ++ +++ ++
2763 MTRYSAPPG 1a, 1b, 2, 3, 4, 5a, 6 + + +++ + + + + + + + +
2889 LSAFSLHSY# [40] 1a, 1b, 5a +++ + + +++ + + ++ + + + +
LSAFTLHSY 3 +++ + + +++ + + ++ + + + +
LSAFTLHGY 4 +++ + + +++ + + + + + + +
#-indicates that the epitope has been experimentally proven to be a true positive.
a–italics indicates amino acid(s) variation in epitope in comparison to the predicted epitope.















Table 5 Binding affinity scores of predicted epitopes and their variants to common HLA class II allele types prevalent
in South Africa
Position Predicted epitopes Genotype of epitope HLA II- DRB1 allele typesa
HLA-DRB1*03:01 HLA-DRB1*04:01 HLA-DRB1*11:01 HLA-DRB1*15:01
E2
507 YCFTPSPVV 1a, 1b, 2, 3, 4, 5a, 6 + +++ + +++
695 NIVDTQYLY 5a + +++ + +++
NS2
938 LLHLGRLTG 5a + ++ +++ +
1025 LLAPITAYA 1a, 3, 4, 5a, + ++ +++ ++
NS3
1129 DLYLVTRHA 1a, 1b, 5a + + +++ +
1131 YLVTRHADV 1a, 1b, 5a + + +++ +
1391 LIFCHSKKK 1b, 2, 3, 4, 5a, 6 + + +++ +
1417 YYRGLDVAV 5a + +++ ++ +
1464 FSLDPTFTI 1a, 1b, 2, 5a + +++ +++ +
1535 TTVRLRAYL 3, 5a, 6 + + + +++
1562 FTGLTNIDA 5a + +++ ++ +
1666 VVAALAAYC 5a + + + +++
NS4B
1774 YLAGLSTLP 1a, 1b, 2, 3, 4, 5a, 6 + +++ + +
1919 LIAFASRGN 1a, 1b, 2, 3, 4, 5a, 6 ++ +++ +++ +++
1920 IAFASRGNH 1a, 1b, 2, 3, 4, 5a, 6 + + +++ +
NS5A
1994 WLQAKLLPQ 5a + ++ +++ +
2099 YHYITGVTQ 5a + ++ +++ ++
NS5B
2450 LLRHHNLVY 1a, 3, 5a + ++ ++ +++
2579 LIVYPDLGV 2, 3, 4, 5a, 6 + + + +++
a+++ indicates high binding affinity (<50 IC50nm), ++ indicates medium binding affinity (>50 IC50nm, <500 IC50nm), + indicates poor binding affinity (>500 IC50nm).
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multiple components combining core, E1, and E2 pro-
teins; and conserved T-cell epitopes in the NS proteins
has been suggested to be a good vaccine candidate for
HCV [48].
High number of epitopes was predicted for HLA class
II as compared to class I. The findings of this study are
consistent with a study by Shehzadi et al. that predicted
epitopes in genotype 3 from Pakistan. The study showed
that majority of predicted epitopes were found in the
NS3 protein for both HLA class I and HLA class II alleles
and most of the epitopes were conserved among different
genotypes [49]. Although the NS3 region is one of the
conserved regions in HCV, variability in the nucleotide
and amino acids has been reported by several studies
in the same genotype and also in different genotypes
[50,51]. A recent study that analysed 1568 NS3-protease
sequences from genotypes 1–6 reported that the proteaseamino acids sequence was moderately conserved and
majority of the amino acids clustered in small regions.
Of the 181 amino acids analysed 47% showed <1% vari-
ability among all HCV genotypes, and 17.1% amino acid
positions showing >25.1% variability [51]. The NS3 is
considered to be a good cellular target candidate for a
therapeutic vaccine [52] since majority of the HCV viral
epitopes recognized by CD8+ and CD4+ T-cells are lo-
cated in the NS3 region [53-56]. The NS3 specific CD4+
and CD8+ T-cell responses were reported in patient re-
sponders to interferon therapy [57] and in spontaneous
clearance of HCV [58].
Most of the predicted epitopes in the study sequence
were found to be conserved across different HCV geno-
types with a higher number of epitopes conserved at the
anchor residues. The anchor residues are important for
epitope high binding affinity to HLA [59]. Conserved
epitopes might influence the immunogenic potential
Gededzha et al. Virology Journal 2014, 11:187 Page 11 of 13
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of immune escape [60]. For a vaccine to be effective globally
the selected epitopes must cover HLAs of different popu-
lations and it must also be conserved among different
genotypes. The high mutation rates of viral epitopes and
HLA polymorphisms are some of the challenges that are
associated with the development of peptide vaccines [61].
Successful epitope vaccine design requires a broad know-
ledge of HCV genotype diversity. This will help in the
proper selection of conserved HCV-specific T-cell epi-
topes that will help in avoiding HCV immune evasion
[62]. This study attempted to ensure maximal coverage of
HLA polymorphism and different genotypes by analyzing
conserved epitopes considering different HLA alleles.
Majority of the epitopes predicted from HCV proteins
isolated from South African genotype 5a were good
binders against HLA alleles that are found worldwide.
HLA is both polygenic and polymorphic, and the pool of
HLA molecules differs for every individual. Different
HLA alleles bind peptides with a particular sequence
pattern [63]. For an HLA allele to be covered by a set of
epitopes, at least one of the epitopes should be capable of
inducing an immune response when bound to the corre-
sponding HLA molecule [46]. The epitopes predicted in
this study bind to many HLA alleles including the ones
common in South Africa and can be used for designing
good vaccine candidates that will eventually work in gen-
etically diverse populations. In-vitro and in-silico studies
have showed that HLA alleles preferentially bind to
conserved regions of viral proteins in human viruses [64].
Very few epitopes were found to be experimentally true
positive, however this can be due to the fact that most of
the previous studies focused on genotype 1. A limitation of
the study was a lack of in-vivo and in-vitro studies to
confirm the predicted immunogenic epitopes, which will be
the focus of future studies. However in-silico studies still
provide the basis for designing good vaccine candidates.
In conclusion, the results of this study demonstrated
antigenic T-cell epitopes that are conserved among
genotypes and good HLA binders derived from genotype
5a sequences that can be good candidates for vaccine
development. Predicted epitopes analysed in this study
will contribute to the future design of an efficient vaccine
with the use of conserved epitopes to avoid variation in
genotypes and as such, it will be able to induce broad HCV
specific immune responses. Conserved epitopes among
different genotypes will be experimentally tested in the
future to determine their involvement in immune response.
Methods
Ethical statement
The study was approved by the Medunsa Research and
Ethics Committee of the Faculty of Health Sciences at
the University of Limpopo as project no MREC/p/142/2009:PG. The MREC is registered as an Independent
Review Board with a reference no (IRB00005122).Prediction of T-cell epitopes
Genotype 5a full-length sequences available in the GenBank
and 6 of the near full length sequences generated from a
previous study conducted by our group [24] were aligned
and consensus sequences created using BioEdit [65] for
the prediction of T-cell epitopes. For HLA class I, predic-
tion for binding alleles was performed using ProPred I
(http://www.imtech.res.in/raghava/propred1/) at a 4% de-
fault threshold by keeping the proteosome and immuno-
proteosome filters on at 5% threshold. ProPred 1 predicts
antigenic epitopes for 47 HLA class I alleles [44]. For
HLA class II, prediction was performed using ProPred
(http://www.imtech.res.in/raghava/propred/) at a 3% de-
fault threshold. ProPred predicts antigenic epitopes for
51 HLA class II alleles [45].Antigenicity of the epitopes
The Antigenicity score of all the predicted epitopes were
analysed using VaxiJen v2.0 online antigen prediction
(www.ddg-pharmfac.net/vaxijen/). Epitopes having anti-
genic score >0.5 were selected as antigenic. Vaxijen server
performed well with 87% accuracy at a threshold of 0.5
antigenic score for viruses. VaxiJen v2.0 allows antigen
classification based on the physicochemical properties of
proteins without recourse to sequence alignment.Epitope conservation analysis
All predicted epitopes were analyzed for conservation
using the IEDB database (http://tools.immuneepitope.org/
tools/conservancy/iedb_input) at a threshold of 100%
conservation in comparison with 406, 221, 98, 33, 45,
45 randomly selected sequences from each of the HCV
genotypes 1a, 1b, 2, 3, 4 and 6 respectively. The epitopes
were considered conserved in another genotype if it shows
100% identity across the epitope in at least 70% of
sequences in that genotype in the randomly selected
sequences used in this study, downloaded from the public
database. In addition, epitope variants that were conserved
in at least 70% of the sequences were analysed for conser-
vancy for anchor residues at positions 2 and 9 for HLA
class I and positions 1, 4, 6 and 9 for HLA class II.Validation of predicted epitopes
All the predicted epitopes were submitted to IEDB
database (http://www.immuneepitope.org/) to confirm
if they had been tested previously by other studies. The
immuneepitope database contains experimentally con-
firmed data about antibody, T-cell epitopes, HLA binding,
HLA restriction and HLA class.
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For epitope prediction binding to common HLA alleles
found in South Africa, the IEDB epitope analysis tool
(http://tools.immuneepitope.org/tools/conservancy/iedb_
input) was used for HLA class I using the artificial neural
network (ANN) algorithm [66] on the IEDB server, while
for Class II ProPred (http://www.imtech.res.in/raghava/
propred/) at a 3% default threshold was used. ProPred
predicts antigenic epitopes for 51 HLA class II alleles
[54]. The most common South African alleles were
found in published literature [67].
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